Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)
Key Points
To evaluate the role of lymph node metastasis as a prognostic factor in metastatic urothelial carcinoma patients treated with pembrolizumab.
Retrospective analysis of patients with mUC
Inclusion of patients treated with pembrolizumab
Assessment of outcomes based on the presence of lymph node metastasis and histological variants
Lymph node metastasis associated with improved outcomes
Specific for patients with histological variants of urothelial carcinoma
Provides evidence for its role as a favorable prognostic factor
Abstract
The presence of LNM may be a HV-UC-specific prognostic factor of a favorable outcome in patients with mUC receiving pembrolizumab as second-line or later therapy.